PMT Biosciences — Executive Summary

PMT Biosciences was founded with a simple but urgent mission: to change the course of Parkinson's disease for patients and families who have been told that progression is inevitable. For decades, Parkinson's treatment has focused on symptom relief, while disease progression remains unaddressed. PMT exists to bring hope where none has existed before.

The company emerged from firsthand clinical exposure to metabolic and cofactor-driven biological pathways and the realization that, despite decades of scientific interest, these mechanisms had never been rigorously developed, manufactured, or tested as a potential disease-modifying therapy for Parkinson's. PMT is committed to the rigorous, disciplined scientific work needed to move this biology from observation into evidence that patients and clinicians can trust.

Over the past several years, PMT has transitioned from early patient and clinician discovery into a structured, science driven development program. Through coordinated research programs in the U.S. and Italy, PMT is completing development of its lead fermentation-derived therapeutic candidate, including novel extraction, purification, and stabilization methods designed to preserve biologically meaningful cofactor activity. This work has positioned the program to advance into formal cGMP development.

In 2026, PMT will take a critical step forward. cGMP certification and preclinical studies are scheduled to begin in April 2026, marking the transition from preparation to execution. These studies are designed not only to meet regulatory standards, but to answer the questions that matter most to patients: Who might benefit? Why? And how can treatment be delivered responsibly and effectively?

PMT's clinical pathway is anchored by its partnership with Humanitas Research Hospital in Milan and Dr. Alfonso Fasano, a globally recognized leader in Parkinson's disease. Together, they have aligned on a combined Phase I/II EMA strategy, reflecting confidence in the biological rationale and readiness of PMT's therapeutic program. This EMA-first approach is built to move with urgency and care, maintaining rigorous standards while laying the groundwork for FDA bridging.

By the end of 2025, PMT had evolved into a global, execution-ready company with a European holding structure, validated clinical partnerships, and growing recognition within the Parkinson's and global health communities, including participation in World Health Organization (WHO) wellbeing and aging initiatives. As PMT enters 2026, the focus is clear: advance into preclinical studies, initiate cGMP manufacturing, and prepare for Phased clinical trials—always with patients at the center of every decision.

PMT is raising capital to fund its 2026–2027 execution phase, including cGMP manufacturing, preclinical studies, and preparation for an EMA-aligned combined Phase I/II clinical program.

The raise is structured to provide sufficient runway to reach key regulatory and clinical inflection points without reliance on grant timing, while continuing to pursue non-dilutive funding opportunistically. This strategy enables PMT to preserve ownership, minimize dilution, and deploy capital directly toward value-creating milestones that materially de-risk the program.

PMT Biosciences is building what does not yet exist in Parkinson's: a credible, evidence-based path toward disease modification, which is grounded in biology, validated by clinicians, and ready for execution.